DP20CQ
Intervention1 paper3 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
- Cells1
Outcomes
3Cell viability
no changein human cells1
1 study
Cell viability
no changein human cells1
DP20CQ has no effect on cell viability in human cells.
CellsDP20CQ niosomesumbilical cord stroma-derived mesenchymal stromal cells
Innovative niosome screening for efficient gene delivery in senescent primary umbilical cord stroma-derived MSCs · Drug delivery · 8 Oct 2026
endosomal escape
upin human cells1
1 study
endosomal escape
upin human cells1
DP20CQ increases endosomal escape in human cells.
CellsDP20CQ niosomesumbilical cord stroma-derived mesenchymal stromal cellsparticularly at DOTMA/DNA ratio 10/1
Innovative niosome screening for efficient gene delivery in senescent primary umbilical cord stroma-derived MSCs · Drug delivery · 8 Oct 2026
Transgene expression
upin human cells1
1 study
Transgene expression
upin human cells1
DP20CQ increases transgene expression in human cells.
CellsPalbociclib-induced senescence; compared with LipofectamineDP20CQ niosomesumbilical cord stroma-derived mesenchymal stromal cells10/1 and 15/1 DOTMA/DNA ratios
Innovative niosome screening for efficient gene delivery in senescent primary umbilical cord stroma-derived MSCs · Drug delivery · 8 Oct 2026